MRG002
1 product
3 abstracts
2 targets
Target
HER2Target
PD-1Abstract
Preliminary safety and efficacy of TQB2930, a HER2-targeted bispecific antibody in patients with advanced breast cancer: Results from a phase 1b study.Org: Department of Medical Oncology, Harbin Medical University Cancer Hospital, Harbin, China, Harbin Medical University Cancer Hospital, Harbin, China, Chongqing University Cancer Hospital, Chonqqing, China, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China, Department of Medical Oncology, State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center,
Abstract
Antibody-drug conjugates (ADC) in patients with advanced/metastatic HER2-low expressing breast cancer: A systematic review and meta-analysis.Org: Catholic University of Pelotas, RS, Brazil, Pelotas, Brazil, Universidade Estadual do Centro Oeste (UNICENTRO), Guarapuava, Brazil, Federal University of Amazonas - UFAM, Manaus, Brazil, University of Brasilia, Brasilia, Brazil,
Abstract
ADC vs HP dual-antibody for HER2-positive advanced breast cancer after failed to TKI.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, The Fifth Medical Center of Chinese PLA General Hospital, Beijing, Beijing, China, Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China, The Fifth Medical Centre of Chinese PLA General Hospital, Beijing, China, Department of Breast Cancer, the Fifth Medical Center Affiliated to PLA General Hospital, Beijing, China,
Product
MRG002 + HX008